Multiple electrode aggregometry and P2Y₁₂ antagonists

• References

• 1 Sibbing D, Braun S, Jawansky S. et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thomb Haemost 2008; 99: 121-126.
• 2 Tóth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
• 3 Mueller T, Dieplinger B, Poelz W. et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer – comparison with two flow cytometric methods. Thromb Res 2007; 121: 249-258.
• 4 Seyfert UT, Haubelt H, Vogt A. et al. Variables influencing Multiplate^™ whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206.
• 5 Mengistu AM, Wolf MW, Boldt J. et al. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. Cardiothorac Vasc Anesth 2008; 22: 40-46.
• 6 http://www.multiplate.net Accessed on January 26, 2008.
• 7 Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP. et al. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100^™). Platelets 2007; 18: 491-46.
• 8 Perneby C, Wallén NH, Hofman-Bang C. et al. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. Thromb Haemost 2007; 98: 1316-1322.
• 9 Neubauer H, Lask S, Engelhardt A. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
• 10 Steinhubl SR, Oh JJ, Oestreich JH. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
• 11 Fox SC, Behan MWH, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004; 35: 39-46.
• 12 http://www.themedicinescompany.com/prod ucts_cangrelor.shtml
• 13 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
• 14 Parikh SA, Beckman JA. Contemporary use of clopidogrel in patients with coronary artery disease. Curr Cardiol Rep 2007; 9: 257-263.
• 15 Williams ET, Jones KO, Ponsler GD. et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008 Mar 27 [E-pub ahead of print]..
• 16 Frelinger III AL, Jakubowski JA, Li Y. et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192-200.